Key result
Targeted hormone therapies show promise for modulating neurohormonal imbalance in congestive heart failure.
Why the study?
Do hormone treatments improve clinical outcomes in patients with congestive heart failure?
Do hormone treatments improve clinical outcomes in patients with congestive heart failure?
This review highlights the potential of various hormone-based therapies to address the neurohormonal imbalance central to the pathophysiology of congestive heart failure.
Answers are grounded in this paper and cite their sources.
Supports targeted hormone modulation in heart failure; leaves open routine adoption pending dedicated randomized trials.
The common ultimate pathological feature for all cardiovascular diseases, congestive heart failure (CHF), is now considered as one of the main public health burdens that is associated with grave implications. Neurohormonal systems play a critical role in cardiovascular homeostasis, pathophysiology, and cardiovascular diseases. Hormone treatments such as the newly invented dual-acting drug valsartan/sacubitril are promising candidates for CHF, in addition to the conventional medications encompassing beta receptor blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists. Clinical trials also indicate that in CHF patients with low insulin-like growth factor-1 or low thyroid hormone levels, supplemental treatment with growth hormone or thyroid hormone seems to be cardioprotective; and in CHF patients with volume overload the vasopressin antagonists can relieve the symptoms superior to loop diuretics. Furthermore, a combination of selective glucocorticoid receptor agonist and mineralocorticoid receptor antagonist may be used in patients with diuretic resistance. Finally, the potential cardiovascular efficacy and safety of incretin-based therapies, testosterone or estrogen supplementation needs to be prudently evaluated in large-scale clinical studies. In this review, we briefly discuss the therapeutic effects of several key hormones in CHF.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2018) conducted a review in Congestive heart failure. Hormone treatments was evaluated. Hormone treatments, such as neprilysin inhibitors and vasopressin antagonists, offer promising therapeutic strategies for modulating neurohormonal imbalance in patients with congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: